Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Safety and Dosimetry Study of ¹⁷⁷Lu-FAPI in Patients With FAP-Positive Malignancies

NCT07681141 is registered in ClinicalTrials.gov with First Affiliated Hospital of Fujian Medical University as lead sponsor.

NCT NCT07681141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07681141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Safety and Dosimetry Study of ¹⁷⁷Lu-FAPI in Patients With FAP-Positive Malignancies
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 1, 2025
Completion date
December 31, 2027
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with advanced metastatic fap-positive tumors